| 000 | 01342 a2200361 4500 | ||
|---|---|---|---|
| 005 | 20250517182314.0 | ||
| 264 | 0 | _c20180724 | |
| 008 | 201807s 0 0 eng d | ||
| 022 | _a1533-1601 | ||
| 024 | 7 |
_a10.1177/0192623317737066 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBrown, Jacques P | |
| 245 | 0 | 0 |
_aAntiresorptives: Safety Concerns-Clinical Perspective. _h[electronic resource] |
| 260 |
_bToxicologic pathology _c10 2017 |
||
| 300 |
_a859-863 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadverse effects |
| 650 | 0 | 4 |
_aBisphosphonate-Associated Osteonecrosis of the Jaw _xpathology |
| 650 | 0 | 4 |
_aBone Density Conservation Agents _xadverse effects |
| 650 | 0 | 4 |
_aBone Remodeling _xdrug effects |
| 650 | 0 | 4 | _aClinical Trials, Phase III as Topic |
| 650 | 0 | 4 |
_aDenosumab _xadverse effects |
| 650 | 0 | 4 |
_aDiphosphonates _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFemoral Fractures _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 | _aObservational Studies as Topic |
| 650 | 0 | 4 |
_aOsteoporosis _xdrug therapy |
| 650 | 0 | 4 | _aRisk Factors |
| 773 | 0 |
_tToxicologic pathology _gvol. 45 _gno. 7 _gp. 859-863 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/0192623317737066 _zAvailable from publisher's website |
| 999 |
_c27718016 _d27718016 |
||